MiNK Therapeutics, Inc. (INKT)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MiNK Therapeutics, Inc. (INKT) trades at $11.43 with AI Score 30/100 (Grade D). MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies. Market cap: $56.97M, Sector: Healthcare.
Price live · AI analysis from May 4, 2026Analyst Coverage for INKT: INKT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates INKT against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
INKT: 1/1 perspectives are bearish.
How is this calculated? →MiNK Therapeutics, Inc. (INKT) Healthcare & Pipeline Overview
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, specializes in developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. Their lead candidate, AGENT-797, targets myeloma and is in Phase 1 trials, positioning them in the competitive immunotherapy landscape.
What Is the Investment Thesis for INKT?
MiNK Therapeutics presents a focused investment opportunity within the burgeoning field of cell therapy. The company's lead asset, AGENT-797, currently in Phase 1 trials, targets multiple myeloma, a significant market with unmet needs. Successful clinical trial outcomes for AGENT-797 could drive substantial value. The company's allogeneic, off-the-shelf approach offers advantages in terms of scalability and accessibility compared to autologous cell therapies. Key value drivers include the progression of AGENT-797 through clinical trials, expansion of the pipeline to address other cancer indications, and potential partnerships or acquisitions. Ongoing clinical trial risks and competition from established players in the immunotherapy space represent potential challenges. The company's market capitalization is approximately $70 million as of May 2026.
Based on FMP financials and quantitative analysis
INKT Key Highlights
- AGENT-797, MiNK Therapeutics' lead product candidate, is currently in Phase 1 clinical trials for the treatment of various myeloma diseases.
- MiNK Therapeutics operates as a subsidiary of Agenus Inc., providing access to resources and expertise in the immunotherapy field.
- The company focuses on allogeneic, off-the-shelf iNKT cell therapies, offering potential advantages in scalability and accessibility compared to autologous approaches.
- MiNK Therapeutics was incorporated in 2017, indicating a relatively young company in the competitive biotechnology landscape.
- The company has 23 employees, reflecting its current stage as a clinical-stage biopharmaceutical company.
Who Are INKT's Competitors?
INKT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AGEN Agenus Inc. | $3.50 | +0.29% | $145.75M | — |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are INKT's Key Strengths?
- Novel iNKT cell therapy platform.
- Focus on allogeneic, off-the-shelf therapies.
- Lead product candidate in Phase 1 clinical trials.
- Subsidiary of Agenus Inc.
What Are INKT's Weaknesses?
- Early-stage clinical development.
- Limited financial resources.
- Small number of employees.
- Reliance on a single lead product candidate.
What Could Drive INKT Stock Higher?
- Announcement of Phase 1 clinical trial results for AGENT-797 in myeloma diseases (estimated Q4 2026).
- Initiation of Phase 2 clinical trials for AGENT-797 in expanded indications (estimated Q2 2027).
- Progress in developing new iNKT cell therapy candidates for other cancer types.
- Potential for strategic partnerships or collaborations with larger pharmaceutical companies.
What Are the Key Risks for INKT?
- Financial-distress signal — its Altman Z-Score of -23.64 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure of AGENT-797 in clinical trials.
- Competition from other companies developing cell therapies.
- Regulatory delays or setbacks.
- Dependence on Agenus Inc. for resources and support.
- Challenges in raising additional capital.
What Are the Growth Opportunities for INKT?
- Expansion of AGENT-797 Clinical Trials: MiNK Therapeutics has the opportunity to expand the clinical trials for AGENT-797 beyond Phase 1 and to investigate its efficacy in treating other myeloma diseases. Positive results in these expanded trials could significantly increase the value of AGENT-797 and attract potential partnerships. The global myeloma market is projected to reach $37.5 billion by 2030, providing a substantial market opportunity for successful therapies.
- Development of New iNKT Cell Therapies: MiNK Therapeutics can leverage its expertise in iNKT cell therapy to develop new product candidates targeting different types of cancer and immune-mediated diseases. This diversification of the pipeline would reduce the company's reliance on AGENT-797 and expand its potential market reach. The broader cell therapy market is expected to continue growing at a rapid pace, offering numerous opportunities for innovative therapies.
- Strategic Partnerships and Collaborations: MiNK Therapeutics could pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its iNKT cell therapies. These partnerships could provide access to additional funding, expertise, and resources, enhancing the company's ability to bring its therapies to market. Collaboration can help navigate the complex regulatory landscape and accelerate clinical trials.
- Advancements in iNKT Cell Engineering: MiNK Therapeutics has the opportunity to further enhance its iNKT cell therapy platform through advancements in cell engineering. This could involve improving the targeting specificity, efficacy, and safety of iNKT cells, leading to more effective and differentiated therapies. Investment in research and development is crucial for staying ahead in the competitive cell therapy field.
- Geographic Expansion: MiNK Therapeutics can expand its geographic reach by conducting clinical trials and seeking regulatory approvals in different countries. This would allow the company to access a larger patient population and increase the potential market for its therapies. The global market for cell therapies is expanding, with increasing demand in Asia and Europe.
What Opportunities Does INKT Have?
- Expansion of clinical trials to other indications.
- Strategic partnerships with larger pharmaceutical companies.
- Advancements in iNKT cell engineering.
- Growing market for cell therapies.
What Threats Does INKT Face?
- Clinical trial failures.
- Competition from established players in the immunotherapy space.
- Regulatory hurdles.
- Difficulty in raising capital.
What Are INKT's Competitive Advantages?
- Proprietary iNKT cell therapy platform.
- First-mover advantage in developing allogeneic iNKT cell therapies.
- Strong intellectual property portfolio protecting its technologies.
What Does INKT Do?
MiNK Therapeutics, Inc., established in 2017 and based in New York City, is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies. These therapies aim to treat cancer and other immune-mediated diseases. The company's primary focus is on leveraging the unique properties of iNKT cells to create effective and accessible treatments. Their lead product candidate, AGENT-797, is an off-the-shelf, allogeneic iNKT cell therapy currently in Phase 1 clinical trials for the treatment of various myeloma diseases. MiNK Therapeutics operates as a subsidiary of Agenus Inc., allowing it to benefit from Agenus' resources and expertise in the broader immunotherapy field. Formerly known as AgenTus Therapeutics, Inc., MiNK Therapeutics is committed to advancing iNKT cell therapy as a novel approach to combatting cancers and immune disorders, striving to improve patient outcomes through innovative therapeutic solutions.
What Products and Services Does INKT Offer?
- Develop allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies.
- Focus on treating cancer and other immune-mediated diseases.
- Conduct Phase 1 clinical trials for their lead product candidate, AGENT-797.
- Target various myeloma diseases with AGENT-797.
- Operate as a subsidiary of Agenus Inc.
- Engage in the discovery and commercialization of novel therapies.
How Does INKT Make Money?
- Develop and out-license or sell allogeneic iNKT cell therapies.
- Generate revenue through research grants and collaborations.
- Potentially generate revenue from commercial sales of approved therapies in the future.
What Industry Does INKT Operate In?
MiNK Therapeutics operates within the rapidly evolving biotechnology sector, specifically focusing on cell therapy. The cell therapy market is experiencing significant growth, driven by advances in immunotherapy and the potential for personalized medicine. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms developing various cell-based therapies. MiNK Therapeutics' focus on allogeneic iNKT cell therapies differentiates it from companies primarily focused on autologous CAR-T cell therapies. The increasing prevalence of cancer and immune-mediated diseases fuels the demand for innovative therapeutic approaches, positioning MiNK Therapeutics within a high-growth market.
Who Are INKT's Key Customers?
- Patients suffering from various myeloma diseases.
- Healthcare providers seeking innovative treatment options.
- Pharmaceutical companies interested in licensing or acquiring novel cell therapies.
MiNK Therapeutics, Inc. (INKT) Valuation Context
Valued at $56.97M, INKT is classified as a micro-cap stock. Relative to its peer group, INKT's quantitative score of 30/100 is below the peer average of 78/100.
ROE 76%Key Financial Metrics
Return on equity for MiNK Therapeutics, Inc. stands at 76.0%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -10.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.38 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -22.2%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
MiNK Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -23.64 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project MiNK Therapeutics, Inc. revenue of about $125K for fiscal 2026, with EPS near $-2.75.
INKT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in MiNK's future prospects, indicating that key stakeholders believe in the company's direction.
- Community sentiment has shifted positively as discussions around innovative therapies have gained traction, reflecting optimism about product pipelines.
- Recent partnerships in the biotech space have sparked interest, positioning MiNK favorably among peers and enhancing its credibility.
- The overall market for therapeutics is expanding, and MiNK's focus on novel treatments aligns well with growing demand for effective solutions.
Bear Case
- Concerns about regulatory hurdles persist, as the biotech industry faces scrutiny that could delay product launches and impact investor sentiment.
- Community discussions also reflect skepticism regarding the scalability of MiNK's technology, raising questions about its long-term viability.
- Recent market volatility has heightened risk aversion, leading some investors to shy away from speculative biotech stocks like MiNK.
- Insider selling activity in the past month has raised red flags, suggesting that some stakeholders may lack confidence in the company's immediate outlook.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
INKT Latest News
-
12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga · Jun 16, 2026
-
12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga · May 15, 2026
-
Earnings Scheduled For May 15, 2026
benzinga · May 15, 2026
-
Earnings Scheduled For November 14, 2024
benzinga · Nov 14, 2024
INKT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for INKT.
Price Targets
Wall Street price target analysis for INKT.
INKT MoonshotScore
What does this score mean?
The MoonshotScore rates INKT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jennifer S. Buell
CEO
Jennifer S. Buell is the CEO of MiNK Therapeutics, bringing extensive experience in the biopharmaceutical industry. Her background includes leadership roles in drug development, clinical operations, and strategic planning. She has a proven track record of advancing novel therapies through clinical trials and navigating the regulatory landscape. Her expertise spans various therapeutic areas, including oncology and immunology. She is responsible for overseeing the company's strategic direction and driving the development of its iNKT cell therapy platform.
Track Record: Under Jennifer Buell's leadership, MiNK Therapeutics has advanced AGENT-797 into Phase 1 clinical trials. She has focused on building a strong team and securing funding to support the company's research and development efforts. Her strategic decisions have positioned MiNK Therapeutics as a key player in the emerging field of iNKT cell therapy.
INKT Healthcare Stock FAQ
What does MiNK Therapeutics, Inc. do?
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies. Their primary focus is on creating innovative treatments for cancer and immune-mediated diseases. Their lead product candidate, AGENT-797, is currently in Phase 1 clinical trials for the treatment of various myeloma diseases. The company aims to leverage the unique properties of iNKT cells to provide effective and accessible therapies for patients in need.
What do analysts say about INKT stock?
As of May 2026, there is limited analyst coverage specifically for MiNK Therapeutics (INKT) due to its relatively small market capitalization and early stage of clinical development. However, the biotechnology sector in general is viewed as having high growth potential, particularly in the area of cell therapy. Investors should closely monitor the progress of AGENT-797 through clinical trials and assess the company's financial resources and strategic partnerships. The company's valuation will likely be highly dependent on the clinical trial outcomes and regulatory milestones.
What are the main risks for INKT?
The main risks for MiNK Therapeutics include the inherent uncertainties associated with clinical-stage drug development. Failure of AGENT-797 in clinical trials would have a significant negative impact on the company's value. Competition from larger pharmaceutical companies and other biotech firms developing cell therapies poses another risk. Regulatory hurdles and potential delays in obtaining marketing approvals are also important considerations. Additionally, the company's reliance on Agenus Inc. for resources and support creates a dependency risk. Securing additional funding to support ongoing research and development is crucial for the company's long-term success.
What are the key factors to evaluate for INKT?
MiNK Therapeutics, Inc. (INKT) holds an AI score of 30/100 (low). Not financial advice.
How frequently does INKT data refresh on this page?
INKT prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven INKT's recent stock price performance?
MiNK Therapeutics, Inc. (INKT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel iNKT cell therapy platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider INKT overvalued or undervalued right now?
Valuing MiNK Therapeutics, Inc. (INKT) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying INKT?
Before investing in MiNK Therapeutics, Inc. (INKT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Clinical trial outcomes are inherently uncertain.
- Market conditions and competitive landscape may evolve.